Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Dickinson, Michael; Carlo‐Stella, Carmelo; Morschhauser, Franck; Bachy, Emmanuel; Corradini, Paolo; Iacoboni, Gloria; Khan, Cyrus; Wróbel, Tomasz; Offner, Fritz; Trněný, Marek; Wu, Shang‐Ju; Cartron, Guillaume; Hertzberg, Mark; Sureda, Anna; Pérez-Callejo, David; Lundberg, Linda; Relf, James; R. Dixon, Mark; Clark, Emma; Humphrey, Kathryn; Hutchings, Martin

doi:10.1056/nejmoa2206913

Public

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Published in New England Journal of Medicine • Dec 11, 2022

Authors:

Michael Dickinson

Carmelo Carlo‐Stella

Franck Morschhauser

Abstract

BACKGROUND: The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. Glofitamab is a bispecific antibody that recruits T cells to tumor cells. METHODS: In the phase 2 part of a phase 1-2 study, we enrolled patients with relapsed or refractory DLBCL who ha...

Subject

Medicine

Internal medicine

Discontinuation

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!